Skip to main content
  1. Home
  2. Solutions
  3. Cancer genomics solutions
  4. Liquid Biopsy Research

Precision and consistency in tumor detection and analysis

Liquid biopsy is a revolutionary, non-invasive technique that allows for the detection and analysis of circulating tumor DNA (ctDNA) from a simple blood sample. Unlike traditional tissue biopsies, liquid biopsies offer a less invasive, quicker, and more comprehensive approach for cancer research, tumor analysis, and monitoring.
Agilent provides cutting-edge liquid biopsy solutions designed to advance cancer research. Our next-generation sequencing (NGS) technologies are engineered to deliver high sensitivity and specificity, enabling researchers to detect and analyze ctDNA with unparalleled accuracy.

Key features of our solutions include:

  • High sensitivity: Detect low-frequency mutations with precision
  • Comprehensive analysis: Analyze a wide range of genetic alterations
  • User-friendly format: Enjoy simplified workflows for efficient processing

Harness dual profiling capabilities with Avida target enrichment

Agilent Avida reagents enable both DNA and methylation profiling of a single liquid biopsy sample, supporting high-sensitivity applications such as ctDNA analysis, deep sequencing, and multiomic analysis.
×

Contact Us

Drive discovery with innovative liquid biopsy solutions

Avida target enrichment

Explore novel workflows that enhance multiomics capabilities for translational research, allowing you to extract more information from every sample.

 Download brochure

Cell-free DNA Screen Tape

Quality Control solutions for extracted cfDNA samples to monitor sizing and quantity as part of an intergrated target enrichment NGS workflow.

 Download application note

Avida Performance with ctDNA Reference Samples

The Avida DNA workflow consistently recovers sufficient unique DNA molecules for reliable calls at low variant allele frequencies with a flexible input range.

 Download application note

Considerations for working with liquid biopsy samples

Liquid biopsy samples typically have a low amount of ctDNA, particularly in early-stage cancers, and therefore require highly sensitive techniques for detection and analysis. Sensitivity is crucial to minimize false negatives and maximize the information extracted from precious samples.

Efficient workflows minimize sample loss, reduce turnaround time, and maximize data output from limited samples. Automation and simplified procedures help researchers optimize their liquid biopsy analysis and make it more suitable for potential clinical applications.

The precise quantification of cfDNA is essential for determining sample quality and suitability for downstream analysis. Accurate sizing of cfDNA fragments helps to identify the presence of different fragment types, such as mono-, di-, and tri-nucleosomes. This information is crucial for understanding the integrity of the cfDNA and optimizing downstream applications.

HmwDNA contamination can significantly affect the quality of NGS library preparation and sequencing results. Researchers need reliable methods to detect and quantify hmwDNA contamination to ensure the accuracy and reliability of their data.

Researchers increasingly seek to assess both genetic and epigenetic alterations from the same sample, to gain a more comprehensive understanding of cancer biology. Technologies that enable multiomics analysis from a single, low-input sample are highly desirable, particularly when dealing with limited liquid biopsy material.

For Research Use Only. Not for use in diagnostic procedures.
×

Contact Us